The list of Aurora Cannabis (ACB) pessimists on Wall Street is a long one. Jefferies’ Owen Bennett is among the detractors. The analyst has been on the lookout for signs the company is on the cusp of a meaningful turnaround, but evidence is hard to find. The Canadian pot producer's latest quarterly results provided little reassurance. “First, Canadian sales pressures were more pronounced than we had assumed, with little improvement on the margin profile,” Bennett noted. “Second, given the near-term debt overhang and its high cash burn rate, we raise question marks on whether Aurora's balance sheet is strong enough to support a potential US push.